What nuvonis technologies does

Nuvonis Technologies GmbH is a privately-held Austrian biotech company headquartered in Vienna that develops and supplies cell banks used as substrates in vaccine and viral vector manufacturing. Its product portfolio consists of ready-to-use Vero Cell Banks (R&D and GMP grade) and Avian Cell Banks (R&D and GMP grade), produced under serum and animal-free media conditions and fully tested in accordance with US FDA cGMP (21 CFR), European Pharmacopoeia, and ICH guidelines. The company claims its ready-to-use qualified cell banks can shorten vaccine development timelines by 1-2 years by eliminating the need for customers to internally develop and validate their own cell substrates.

The company monetizes through three revenue streams: one-time licensing/sale of GMP and R&D cell bank products, process development services for upstream and downstream vaccine production optimization, and CMC pharmaceutical consulting covering GMP manufacturing, CDMO management, and regulatory strategy from clinical trial application through commercial production. Its go-to-market is a sales-led, direct B2B motion targeting vaccine manufacturers, biopharmaceutical companies developing viral therapies, and CDMO partners globally, supported by content marketing, industry conference participation, and a multilingual website (German, English, Arabic, Chinese). Notable recent strategic activity includes a Key Technical Partner role in the EU Horizon Europe Vaccine Initiative (2024), selection for GO TOKYO 2026 via the Global Incubator Network (2024), and a GGF24 presentation on an optimized MVA production cell line (2024). No funding rounds, headcount, revenue figures, named customers, founders, or leadership disclosures were found in the source data, representing a material information gap.

Name

nuvonis technologies

Legal name

Nuvonis Technologies GmbH

Website

https://nuvonis.com

Company type

Private

Operating status

Operating

Short description

Nuvonis Technologies is an Austrian biotech company that develops GMP-compliant Vero and Avian cell banks for vaccine and viral vector production, complemented by process development and CMC consulting services for biopharmaceutical manufacturers.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)

Keywords

• Cell bank manufacturing
• Vaccine production services
• Biopharmaceutical consulting
• Viral vector production
• GMP cell substrates

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cell Bank Products: Sale of Vero and avian cell banks (R&D and GMP grade) for vaccine and vector production. Cell banks are provided as ready-to-use Master and Working Cell Banks.
2. Process Development Services: Technical services for developing and optimizing vaccine production processes, including upstream and downstream process development.
3. CMC Pharmaceutical Consulting: Consulting services for biopharmaceutical development including GMP manufacturing, CDMO management, and regulatory strategy from clinical trial to commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Nuvonis Technologies develops, manufactures, and supplies ready-to-use Vero and Avian cell banks in both R&D and GMP grades for use in vaccine and viral vector production, with all banks produced under serum and animal-free media conditions and fully characterized per international regulatory guidelines. In parallel, the company provides process development services for upstream and downstream vaccine production, and CMC pharmaceutical consulting covering GMP manufacturing, CDMO management, and regulatory strategy from clinical trial application through commercial production.

Product overview

Nuvonis is a biotech company providing innovative cell banks for vaccine and vector production. The portfolio consists of four interconnected offerings: Vero Cell Banks (R&D and GMP) and Avian Cell Banks (R&D and GMP) serve as the foundational cell bank products, which can be enhanced through Process Development Services for optimizing vaccine production processes. CMC Pharmaceutical Consulting Services provides end-to-end regulatory and manufacturing support from clinical trials through commercial production.

Differentiator

Problem solved

Functional benefit

Products and services

• Nuvonis Vero Cell Banks (R&D and GMP)

Quantifiable outcome

• Reduces time-to-market by 1-2 years

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Global Incubator Network (GIN)minorStrategic or Co-development Partner · 1 January 2026Nuvonis participated in GIN Pitch event and secured a spot in GO TOKYO 2026 program. This represents participation in an incubator network that provides access to mentorship, networking, and potential investment opportunities in the Asian market.
• EU Horizon Europe Vaccine InitiativecoreStrategic or Co-development Partner · 1 January 2026Nuvonis serves as a Key Technical Partner in the EU Horizon Europe Vaccine Initiative, which is mobilizing against next-generation viral threats. This is a significant European Union funded research program bringing together technical partners to address pandemic preparedness.

Recent moves4 records

Expansion highlights4 records

Direct peers

• ATCC (American Type Culture Collection): Global cell line and cell bank repository supplying authenticated cell substrates for research and commercial bioproduction. Most directly comparable to Nuvonis on cell bank supply for vaccine and biological manufacturing, including Vero and avian cell substrates.
• ECACC (European Collection of Cell Cultures): Public cell line repository supplying authenticated cell substrates for European vaccine and biologics developers. Comparable to Nuvonis as a European-anchored cell bank/cell substrate provider serving vaccine manufacturers.
• IDT Biologika: German vaccine CDMO operating its own cell banks and providing vaccine development and manufacturing services. Closest direct competitor profile: boutique European vaccine CDMO with embedded cell substrate capabilities.

Broad incumbents

• Charles River Laboratories: Large CRO/CDMO offering cell banking, biologics safety testing, and viral vaccine development services. Competes with Nuvonis in GMP cell bank supply and CMC consulting but across a much broader portfolio.
• Lonza Group: Global CDMO providing mammalian and viral vector manufacturing, including cell line development for vaccines and gene therapies. Competes for cell substrate and process development scope but at vastly larger scale and with bundled offerings.
• MilliporeSigma (Merck KGaA Life Science): Major bioprocessing supplier providing cell culture media, cell lines, and viral production platforms. Comparable on cell substrate and bioprocess offerings, though as part of a comprehensive life science tools portfolio.
• Cytiva (Danaher): Bioprocessing and cell culture solutions provider offering media, cell lines, and process development tools for vaccine and viral vector manufacturers. Overlaps with Nuvonis on cell substrate and process development inputs.
• Sartorius AG: Large bioprocessing supplier providing cell line development, bioreactor systems, and process services for biologics and vaccine manufacturers. Comparable on process development and bioprocess inputs at scale.
• Thermo Fisher Scientific (Life Sciences / Patheon): Global life sciences tools and CDMO conglomerate offering cell culture products, viral vector CDMO services, and bioprocess capabilities. Overlaps Nuvonis on cell substrate supply and vaccine/biologics process development.

Emerging players

• Valneva: Specialty vaccine developer that uses Vero cell platform technology for its vaccine pipeline. Comparable through shared reliance on Vero cell substrates, illustrating both the upstream supply opportunity for Nuvonis and the type of customer it serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about nuvonis technologies